Search
forResearch 10 of 1000+
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- Alopecia due to chemotherapeutics, hedgehog inhibitors, targeted antibody therapies and immune checkpoint inhibitors
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
- Cutaneous lupus erythematosus. Diagnostic and therapeutic recommendations of the Polish Dermatological Society
- Recent approaches of antibody therapeutics in androgenetic alopecia
- Anti-CXCL4 monoclonal antibody accelerates telogen to anagen transition and attenuates apoptosis of the hair follicle in mice
- 682 Identification of novel potential therapeutic targets by comparative transcriptomic profiling of physiological and pathological skin wounds ex vivo
- Evaluation of the Hemogram of Breast Cancer Patients Treated by Therapeutic Protocol Based on Immunohistochemical Analysis: A Retrospective Study
- Recent Advances in Drug Development for Hair Loss
Community 2 of 3
- HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
- Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
Learn
— no results
Try a deeper search in learn →